drugset
drugset / Trial / NCT02743078

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

NCT02743078 ↗

Phase 2 Terminated 3 enrolled RTOG Foundation, Inc. NovoCure Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields \[TTFields\] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.

Timeline

Start
2017-05-09
Primary completion
2019-10-15
Completion
2019-10-15

Outcome

Outcome not reported

Stopped: “Treatment now available commercially”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous

Indications

gliosarcoma